THE BUZ ON CANNABIS STOCK




Cannabis Stock 

CANNABIS BUZZ Pure play marijuana stocks are scarce. Most companies in the marijuana industry trade over the counter (OTC), where solid information regarding operations and financials is difficult to retrieve. Exceptions extend to issues such as GW Pharmaceuticals plc (NASDAQ: GWPH), a British biopharmaceutical company that developed two cannabis-based drugs licensed for use outside the United States. Sativex is used to treat muscular contractions in multiple sclerosis patients, and Epidiolex targets epileptic seizures in children. Both drugs have entered Phase 3 clinical stage trials in the United States. GWPH has a $2 billion market cap and had returned 23% year to date (YTD) as of Aug. 15, 2016.

Political and legal obstacles remain the highest hurdles for the marijuana industry in 2016. Four states, Oregon, Washington, Alaska and Colorado, have legalized recreational marijuana, and 25 states plus the District of Columbia have approved cannabis for medicinal purposes. The plant is categorized at the federal level as a Schedule 1 drug, possessing the highest risk for psychological and physical dependence, and more curiously, having no acceptable medical use.

The marijuana stock marketplace rebound we’ve been waiting Top Marijuana Picks   It has finally come. It took some time—longer than the maximum of the marijuana stock marketplace supporters might have appreciated—but pot shares have eventually swung returned up into the black after a disappointing 2017. So even as all of the haters had been sitting
Complete Reading

Medical Marijuana: Canopy Growth In Australia Ontario, Canada-based Canopy Growth Corp. said it has signed a supply agreement with AusCann Group Holdings Ltd. to be its exclusive supplier of medical cannabis for the Australian market. Canopy will transfer a range of medicines for research and commercialization in Australia. The deal will also allow Canopy to
Complete Reading

Tetra Bio-Pharma accelerates its clinical research program in the veterinary market by entering into agreement with Dr. Louis-Philippe de Lorimier Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(TBPMF), today announced that it has added international expert Dr. Louis-Philippe de Lorimier, a board certified veterinary oncologist, to its clinical advisory board for the veterinary market.
Complete Reading

GT Biopharma (OXISD) Announces Development Plan For Non-Opioid Neuropathic Pain Treatment “PainBrake” GT Biopharma Inc. announced today that it has made the required payment to license and develop PainBrake, a non-opioid pain medication, to Accu-Break Pharmaceuticals Inc. The payment allows GT Biopharma (OTCQB: OXISD) to begin the clinical development process and the filing of a
Complete Reading

mCig, Inc., Announces First Quarter 2018 Financial Results — Records $3.1M in Revenue  mCig, Inc. ( OTCQB : MCIG ), a diversified company servicing the legal cannabis, hemp, and CBD markets has today released a summary of its unaudited financial results for the first quarter that ended July 31, 2017. The total recognized sales for the quarter ending July
Complete Reading

Create Account



Log In Your Account